| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/23/2011 | US20110152228 Sprayable pharmaceutical compositions comprising a corticoid and an oily phase |
| 06/23/2011 | US20110152227 Deuterium labelled derivatives of 3-(2-hydroxy-5-methyphenyl)-n,n-diisopropyl-3-phenylpropylamine and methods of use thereof |
| 06/23/2011 | US20110152220 Methods of diagnosing, preventing and treating bone mass diseases |
| 06/23/2011 | US20110152212 Aqueous Formulations |
| 06/23/2011 | US20110152210 Polyphenol compounds for inhibiting proteasome and uses thereof |
| 06/23/2011 | US20110152209 Core 2 GlcNAc-T Inhibitors |
| 06/23/2011 | US20110152207 Use of vitamin d glycosides and sulfates for treatment of disease |
| 06/23/2011 | US20110152206 Therapeutic combinations for use in neoplasia |
| 06/23/2011 | US20110152200 Methods and compositions for inhibition of bcl6 repression |
| 06/23/2011 | US20110152199 Cdca1 peptide and pharmaceutical agent comprising the same |
| 06/23/2011 | US20110152180 Bioactive pentapeptides from rice bran and use thereof |
| 06/23/2011 | US20110152175 Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof |
| 06/23/2011 | US20110152174 Inhibition of secretion from non-neuronal cells |
| 06/23/2011 | US20110152173 TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS |
| 06/23/2011 | US20110152166 Method of modulation of protein phosphorylation-dependent conformational transitions with low molecular weight compounds |
| 06/23/2011 | US20110151579 Secreted Epithelial Stromal-1 Molecules and Uses Thereof |
| 06/23/2011 | US20110151474 Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by ugt1a1 enzyme or whose metabolic intermediate is metabolized by the enzyme |
| 06/23/2011 | US20110151473 Polynucleotides and Polypeptides Encoding Receptors |
| 06/23/2011 | US20110151472 Novel means for the diagnosis and therapy of ctcl |
| 06/23/2011 | US20110151030 Compositions for alleviating inflammation and oxidative stress in a mammal |
| 06/23/2011 | US20110151023 Combination therapy with parp inhibitors |
| 06/23/2011 | US20110151022 Thiotungstate analogues and uses thereof |
| 06/23/2011 | US20110151020 Active substance combination with gemcitabine for the treatment of epithelial cancer |
| 06/23/2011 | US20110151012 Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents |
| 06/23/2011 | US20110150984 Methods of increasing the bioavailability and/or cellular update of drugs |
| 06/23/2011 | US20110150982 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| 06/23/2011 | US20110150979 Methods for diagnosis, prognosis and treatment of primary and metastatic basal-like breast cancer and other cancer types |
| 06/23/2011 | US20110150978 Ph-sensitive block copolymer forming polyionic complex micelles and drug or protein carrier using the same |
| 06/23/2011 | US20110150972 Medical devices having improved performance |
| 06/23/2011 | US20110150936 Anti-tumoral cells |
| 06/23/2011 | US20110150935 Targeted treatment for patients with estrogen receptor negative and progesterone receptor negative breast cancers |
| 06/23/2011 | US20110150934 Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer |
| 06/23/2011 | US20110150919 Compositions and methods for the therapy and diagnosis of breast cancer |
| 06/23/2011 | US20110150910 Methods of inducing an immune response |
| 06/23/2011 | US20110150909 Yeast-Based Vaccines As Immunotherapy |
| 06/23/2011 | US20110150908 Anti-cd70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disorders |
| 06/23/2011 | US20110150906 Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer |
| 06/23/2011 | US20110150905 Human antibodies to human delta like ligand 4 |
| 06/23/2011 | US20110150903 Fgf-r4 receptor-specific antagonists |
| 06/23/2011 | US20110150902 Treating cancer |
| 06/23/2011 | US20110150898 EPHA2 as a therapeutic target for cancer |
| 06/23/2011 | US20110150895 Antibody specifically binding to angiopoietin-2 and use thereof |
| 06/23/2011 | US20110150894 Methods of modulating angiogenesis via trpv4 |
| 06/23/2011 | US20110150893 Anti-trkb monoclonal antibodies and uses thereof |
| 06/23/2011 | US20110150892 Human antibodies that bind lymphocyte activation gene-3 (lag-3) and uses thereof |
| 06/23/2011 | US20110150888 Anti-hepcidin antibodies and methods of use |
| 06/23/2011 | US20110150887 Methods and products relating to gsk3beta regulation |
| 06/23/2011 | US20110150886 Anti-areg/hb-egf antibodies and treatment |
| 06/23/2011 | US20110150884 Crystalline composition of gm-csf/gm-csfr |
| 06/23/2011 | US20110150883 Compositions and methods for the therapy and diagnosis of breast cancer |
| 06/23/2011 | US20110150882 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 06/23/2011 | US20110150881 Inhibitors of extracellular hsp90 |
| 06/23/2011 | US20110150877 Ephrin-b receptor protein involved in carcinoma |
| 06/23/2011 | US20110150876 Prognosis and Treatment of Breast Cancer |
| 06/23/2011 | US20110150874 Fusion proteins, uses thereof and processes for producing same |
| 06/23/2011 | US20110150873 Anti-inflammatory compositions and combinations |
| 06/23/2011 | US20110150870 Fully human anti-human nkg2d monoclonal antibodies |
| 06/23/2011 | US20110150869 Neuroinvasion Inhibitor |
| 06/23/2011 | US20110150868 Diagnostic and therapeutic methods and compositions involving pten and breast cancer |
| 06/23/2011 | US20110150864 Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators |
| 06/23/2011 | US20110150863 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| 06/23/2011 | US20110150860 Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor |
| 06/23/2011 | US20110150853 Mycotoxin-reducing composition |
| 06/23/2011 | US20110150849 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules |
| 06/23/2011 | US20110150840 Detection and Treatment of Glyco-Enzyme-Related Disease |
| 06/23/2011 | US20110150834 Crth2 modulators |
| 06/23/2011 | US20110150833 Benzopyrans and analogs as rho kinase inhibitors |
| 06/23/2011 | US20110150832 Furin-knockdown bi-functional rna |
| 06/23/2011 | US20110150831 Novel naphthyridine derivatives and the use thereof as kinase inhibitors |
| 06/23/2011 | US20110150830 Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents |
| 06/23/2011 | US20110150828 Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
| 06/23/2011 | US20110150768 Compositions and methods for delivering inhibitory oligonucleotides |
| 06/23/2011 | US20110150767 Alpha-substituted and alpha-unsubstituted aromatic amino acid derivatives and compositions thereof for use to treat, diagnose, or monitor a medical condition |
| 06/23/2011 | US20110150765 Frozen compositions and methods for piercing a substrate |
| 06/23/2011 | US20110150763 Triazine derivatives and their therapeutical applications |
| 06/23/2011 | US20110150761 Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders |
| 06/23/2011 | US20110150760 PRLR-Specific Antibody and Uses Thereof |
| 06/23/2011 | US20110150759 Monoclonal antibody 175 tageting the egf receptor and derivatives and uses thereof |
| 06/23/2011 | US20110150757 Compounds for inhibiting ksp kinesin activity |
| 06/23/2011 | US20110145970 Detection and use of low molecular-weight modulators of the cold-menthol receptor trpm8 |
| 06/23/2011 | CA2785064A1 Prostate specific membrane antigen inhibitors |
| 06/23/2011 | CA2784784A1 Fusion polypeptide against eb virus-induced tumor and colicin ia mutant |
| 06/23/2011 | CA2784753A1 Substituted aminothiazolone indazoles as estrogen related receptor-.alpha. modulators |
| 06/23/2011 | CA2784689A1 Local delivery of drugs from self assembled coatings |
| 06/23/2011 | CA2784624A1 Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof |
| 06/23/2011 | CA2784566A1 Heterocyclic compounds and their uses |
| 06/23/2011 | CA2784212A1 Biphotonic photosensitizers, nanoparticles containing the same and their use as drugs |
| 06/23/2011 | CA2784145A1 Methods and compositions related to clot-binding compounds |
| 06/23/2011 | CA2784091A1 Use of a neurofilament peptide for the treatment of glioma |
| 06/23/2011 | CA2784075A1 Inhibitors of sphingosine kinase |
| 06/23/2011 | CA2784067A1 Thiazole derivatives for the treatment of diseases such as cancer |
| 06/23/2011 | CA2783969A1 A novel vaccine that targets tumor vessels as an efficient tool in tumor therapy |
| 06/23/2011 | CA2783393A1 Dendritic high-molecular-weight polymer drug carriers and their conjugates with drugs especially for treatment of solid tumours |
| 06/23/2011 | CA2782889A1 Aminopyrimidines as syk inhibitors |
| 06/23/2011 | CA2782574A1 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment |
| 06/23/2011 | CA2782555A1 3-(indolyl)-or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma |
| 06/23/2011 | CA2782472A1 Method of treating scars and beta-catenin-mediated disorders |
| 06/23/2011 | CA2782213A1 1,7-diazacarbazoles and their use in the treatment of cancer |
| 06/23/2011 | CA2780290A1 Mk2 inhibitors |
| 06/23/2011 | CA2771188A1 Passive solid tumor-targeted pectin-doxorubicin prodrug and preparation method thereof |